Wedbush Remains Bullish on Carbylan Therapeutics (CBYL) Despite Mixed Cor1.1 Results - PT to $14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee
February 1, 2016 4:01 PM ESTPALO ALTO, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced top-line results from COR1.1, its first Phase III trial of Hydros-TA for the treatment of pain associated with osteoarthritis of the knee. Hydros-TA is the companys proprietary formulation of hyaluronic acid which entraps a low-dose corticosteroid, triamcinolone acetonide (TA). Hydros contains the same proprietary hyaluronic acid without the addition of TA.Â
COR1.1 was a 560 patient, international, multi-center, randomized, double-blind study designed to... More
